Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Return on Capital Employed of 6.84% for Q1 2026, up 479.0% year-over-year from 1.18% in Q1 2025, and down 4.01% quarter-over-quarter from 6.58% in Q4 2025.
Bristol Myers Squibb (CELG-RI) Return on Capital Employed (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 17 years of Return on Capital Employed data on file, last reported at 6.84% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 6.84%, up 479.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.84% (up 479.0% YoY), and the FY2025 annual result was 6.79%, up 2509.0% from the prior year.
- Return on Capital Employed retreated to 6.84% in Q1 2026 per CELG-RI's latest filing, from 6.58% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 1.88% in Q1 2023 and troughed at 32.22% in Q4 2024.
- A 5-year average of 10.25% and a median of 6.58% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 2904 bps in 2024, then surged 2564 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 3.21% in 2022, then grew by 1 bps to 3.18% in 2023, then sank by 915 bps to 32.22% in 2024, then soared by 80 bps to 6.58% in 2025, then retreated by 4 bps to 6.84% in 2026.
- Business Quant data shows CELG-RI's Return on Capital Employed at 6.84% in Q1 2026, 6.58% in Q4 2025, and 9.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 9.49% |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 42.94% |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 28.18% |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 16.47% |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.22% |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 15.87% |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 21.53% |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -10.20% |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -6.84% |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | -6.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.84% |
| Dec 31, 2025 | -6.58% |
| Sep 30, 2025 | -9.78% |
| Jun 30, 2025 | -11.48% |
| Mar 31, 2025 | -11.63% |
| Dec 31, 2024 | -32.22% |
| Sep 30, 2024 | -26.26% |
| Jun 30, 2024 | -24.29% |
| Mar 31, 2024 | -23.72% |
| Dec 31, 2023 | -3.18% |
| Sep 30, 2023 | -2.78% |
| Jun 30, 2023 | -2.29% |
| Mar 31, 2023 | -1.88% |
| Dec 31, 2022 | -3.21% |
| Sep 30, 2022 | -2.72% |
| Jun 30, 2022 | -2.70% |
| Mar 31, 2022 | -2.78% |
| Dec 31, 2021 | -2.09% |
| Sep 30, 2021 | -16.45% |
| Jun 30, 2021 | -16.00% |